
Shire is set to sweeten its $30 billion bid for Baxalta by offering 40% of the total, or $12 billion, …

Shire has seen an application for its dry eye treatment lifitegrast rejected by the US regulator. The FDA says it …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

